Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9584373 | 0.95 | PDE3A (0.43) | ALDH1A1LMNAHDAC1HDAC2PRKCA | |
| SCHEMBL9583048 | 0.90 | PDE3A (0.40) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL9583144 | 0.90 | PDE3A (0.40) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL9583789 | 0.90 | HDAC1 (0.49) | HDAC1HDAC2P2RY1 | |
| SCHEMBL9583957 | 0.90 | ABCB1 (0.41) | ALDH1A1LMNAHDAC1HDAC2PRKCA | |
| SCHEMBL9583472 | 0.87 | P2RY1 (0.46) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL9584187 | 0.86 | P2RY1 (0.50) | HDAC1HDAC2P2RY1 | |
| SCHEMBL10818024 | 0.85 | PDE3A (0.35) | ALDH1A1LMNAPDE3AP2RY1 | |
| SCHEMBL9583122 | 0.85 | PDE3A (0.47) | ALDH1A1LMNAHDAC1HDAC2PRKCA | |
| SCHEMBL9583322 | 0.84 | PDE3A (0.41) | ALDH1A1LMNAHDAC1HDAC2PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5250535-A | Herpes virus; nontoxic; side effect reduction; humans and veterinary medicine | SYNTEX INC. (US) | 1993-10-05 | — | — | US | disclosed |
| US-4803271-A | Process for preparing guanine derivatives | SYNTEX (U.S.A.) INC. (US) | 1989-02-07 | — | — | US | disclosed |
| US-4612314-A | Substituted 9-(1 or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl) purines as antiviral agent | SYNTEX (U.S.A.) INC. (US) | 1986-09-16 | — | — | US | disclosed |
| EP-0085424-A2 | Substituted 9-(1 or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl)purines as antiviral agent | SYNTEX (U.S.A.) INC. (US) | 1983-08-10 | — | — | EP | disclosed |